Trestle Biotherapeutics
Private Company
Bioengineered Therapies for Kidney Disease
Biotechnology
2-10 employees
Founded 2020
About Trestle Biotherapeutics
Trestle Biotherapeutics is a biotechnology company pioneering treatments for kidney disease through 3D-bioprinted, functional tissues. It develops implantable therapeutics to reduce or eliminate dialysis dependency for patients and offers kidney organoids to accelerate drug discovery for pharmaceutical partners. The company's mission is to make organ replacement therapies accessible to all who need them.
Company Classification
Customer Types
B2B
Business Models
ProductsServicesLicensing
Product & Service Types
Bioengineered therapeutic tissues3D bioprinted organoids for drug discoveryRegenerative medicine platforms
Funding
Total Funding
$1M
No. of Funding Rounds
3
Customers
| Customer | Success Story | Source |
|---|---|---|
| Trestle Bio announced a research collaboration with Humacyte to advance the development of Trestle Bio's novel regenerative medicine products. |
Sign up to Ethos to access the full customer list, plus detailed competitor and product analysis.
Sign up to Ethos